Dr. Jakubowiak on Minimal Residual Disease in Multiple Myeloma
Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease in multiple myeloma.
Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease (MRD) in multiple myeloma.
The combination of the proteasome inhibitor carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone demonstrated significant efficacy in a phase I and II studies in relapsed multiple myeloma.
Disease assessments were made with the use of the International Myeloma Working Group Uniform Response Criteria, with minimal response defined according to European Society for Blood and Marrow Transplantation criteria.
